Why Conventional Immunization Often Fails for High-Homology Targets
Many therapeutically important targets are highly conserved between humans and mice, which limits conventional antibody discovery. In wild-type mouse immunization, this high homology often leads to immune tolerance, resulting in weak immune responses, low antibody titers, and limited recovery of high-affinity candidates.
HUGO-Ab-eKO™ technology is specifically designed to overcome immune tolerance and enable efficient antibody discovery against highly conserved therapeutic targets. By leveraging engineered knockout models and humanized immune systems, this platform enhances antigen recognition, expands B-cell diversity, and improves the recovery of fully human antibodies with strong binding affinity and functional activity. For researchers seeking reliable solutions in antibody discovery for conserved targets, self-antigens, and complex signaling pathways, HUGO-Ab-eKO™ provides a powerful and optimized approach.
HUGO-Ab-eKO™ Workflow: Target Knockout Antibody Discovery Process for High-Homology Therapeutic Targets
Why Choose HUGO-Ab-eKO™ for Difficult Antibody Targets?
HUGO-Mab-eKO™ Accelerates ACVR2A Antibody Development
ACVR2A is a type II transmembrane receptor in the TGF-β superfamily and a promising therapeutic target for muscle atrophy, sarcopenia, obesity, fatty liver disease, and related metabolic disorders. However, the high sequence similarity between human and mouse ACVR2A creates a significant immune-tolerance barrier in wild-type mice, making conventional antibody generation highly challenging.
- {{v2}}
- {{item}}
